An efficient, flexible, modern laboratory that’s brimming with state-of-the-art equipment and follows the latest trends in analyticalchemistry while respecting good old-fashioned chemical processes. Welcome to QUINTA-ANALYTICA’s R&D department.

The core task of this department comprises the development of new analytical methods where (U)HPLC equipment is used for a variety of known detectors like DAD-UV, fluorescence, or ELSD. And for the cases where HPLC is not enough, our LC/MS system with linear ion trap mass spectrometer can be fired up in order to improve selectivity or specificity, especially in trace analyses.

Sounds complex, and indeed it is; but Libor Hoplíček and his team of innovative experts work tirelessly to carry out research in many interesting areas, including the determination and isolation of impurities, accelerated stabilities and degradation studies, de-formulation (reverse engineering) studies, and extractable/leachable analyses to name just a few.

If you’re developing volatile compounds, struggling with in-vitro testing, or looking for someone who has Franz diffusion cell expertise for your permeation studies, look no further. Contact Libor and his team for a no-obligation discussion.

Additional News

  • 17 December 2025

    PF 2026: Thank You from Quinta-Analytica

    In 2025, Quinta-Analytica continued to turn complex development challenges into tangible progress. Our PF 2026 message looks back at key milestones and thanks the partners, clients, and teams who made them possible.

  • 15 December 2025

    IVBE for locally acting drugs: insights from Conscio Science Day in Munich

    Can bioequivalence for locally acting drugs be demonstrated without a single subject in a clinical trial? Yes, if your in vitro bioequivalence (IVBE) toolkit is set up in the right way.

  • 20 November 2025

    Webinar: Streamlined Evidence Strategies for Biosimilars: Analytics, PK and Immunogenicity in focus

    On behalf of Conscio Group, we are pleased to invite you to the upcoming free educational webinar from biosimilar series.